【摘要】 目的评价并比较奥沙利铂与吡哺阿霉素介入治疗原发性肝癌的疗效及安全性。方法分别以奥沙利铂和吡喃阿霉素为主的药物组合灌注栓塞治疗原发性肝癌。评价两组病例的有效率、疾病控制率、肿瘤标志物下降率、临床症状改善率、疾病进展时间、不良反应发生率以判断疗效及安全性。通过两组中疾病进展时间超过12个月的患者的比较判断影响介入治疗远期疗效的因素。结果奥沙利铂组比吡喃阿霉素组的治疗有效牢高,中位疾病无进展时间长,差异有统计学意义(P<0.05)。病灶有无包膜、门静脉受累、术后合并应用抗癌药物对介入治疗的远期疗效有影响(P<0.05)。结论使用奥沙利铂介入治疗原发性肝癌安全、有效,可以提高治疗有效率及疾病无进展时间。但对于远期疗效的影响与吡喃阿霉素没有统计学差异。更多还原

【Abstract】 Objective To evaluate the therapeutic efficacy of oxaliplatin and therarubicin in interventional chemoembolization treatment for primary hepatocellular carcinoma(HCC),and to discuss the difference in clinical safety between oxaliplatin and therarubicin.Methods During the period from Jan.2007 to June 2011,a total of 149 patients with HCC were admitted to authors’ hospital.The patients were divided into two groups.Group oxaliplatin(n = 98) and group therarubicin(n = 51).Interventional chemoembolization with oxaliplatin as the principal anticancer drug was performed in patients of Group oxaliplatin,while interventional chemoembolization with therarubicin as the principal anticancer drug was carried out in patients of Group therarubicin.The response rate,disease control rate,drop rate of tumor markers,improvement rate of clinical symptoms,time to progression(TTP) and toxicity incidence were assessed,and the results were compared between the two groups.The difference in clinical safety between the two groups was analyzed.The factors influencing the long-term efficacy were determined.Results The response rate of group oxaliplatin was significantly higher than that of group therarubicin,and the TTP of group oxaliplatin was significantly longer than that of group therarubicin.The differences between the two groups were statistically significant (P<0.05).Involvement of the capsule and portal vein,postoperative combination use of other anticancer drugs could affect the long-term effect(P<0.05).Conclusion For the treatment of HCC,interventional chemoembolization with oxaliplatin as the principal anticancer drug is safe and effective.This therapy can improve the response rate as well as the TTP,although no statistically significant difference in the long-term effect exists between oxaliplatin and therarubicin.更多还原